

#### C.2.4 Motor developmental delay and unsteadiness (creatine kinase tests)

Component	Description
<b>Review question</b>	In children and infants under 10 years of age who present with motor developmental delay, is a creatine kinase (CK) test accurate in identifying whether muscular dystrophy is present as compared to no test (and as indicated by the reference standard, diagnosis at follow-up)?
<b>Objectives</b>	To evaluate the accuracy of creatine kinase test in aiding a non-specialist in identifying muscular dystrophy in children and infants under 10 who present with motor developmental delay
<b>Study design</b>	Cohort studies, case control if no other evidence identified
<b>Population</b>	All people who present to a non-specialist with motor developmental delay in the following stratifications: <ul style="list-style-type: none"> <li>• children (&lt;10 years old)</li> <li>• infants (&lt;5 years old).</li> </ul>
<b>Setting</b>	Non-specialist setting (for example, primary care)
<b>Index test</b>	Creatine kinase
<b>Reference standard (could be more than one)</b>	<ul style="list-style-type: none"> <li>• Diagnosis of the muscular dystrophy at follow-up</li> <li>• Clinical examination</li> </ul>
<b>Statistical measures</b>	Diagnostic accuracy of creatine kinase: <ul style="list-style-type: none"> <li>• 2x2 tables</li> <li>• Specificity (low false negative)</li> </ul>

	<ul style="list-style-type: none"> <li>• Sensitivity (high)</li> <li>• Positive and negative predictive values</li> <li>• ROC curves and area under the curve.</li> </ul>
<b>Other exclusions</b>	Neonates (infants aged 28 days and under)
<b>Review Strategy</b>	<p>Subgroups where diagnostic tests may be more or less accurate – to investigate heterogeneity:</p> <ul style="list-style-type: none"> <li>• age</li> <li>• muscle injury.</li> </ul> <p>Where possible, results for different types of muscular dystrophies will be analysed separately.</p> <p>Appraisal of methodological quality:</p> <ul style="list-style-type: none"> <li>• The risk of bias each study will be assessed using the QUADAS-II checklist (per target condition).</li> <li>• The overall quality of the evidence will be assessed using an adapted version of GRADE.</li> </ul> <p>Synthesis of data:</p> <ul style="list-style-type: none"> <li>• diagnostic meta-analysis will be conducted where appropriate using hierarchical methods.</li> </ul>